Terbinafine versus itraconazole: a long-term, randomized, double-blind, clinical trial in chronic pulmonary aspergillosis. A pilote study
Background: The frequency of pulmonary aspergillosis has been increasing for decades. Standard oral treatment is associated with tolerability problems and interactions with commonly used medications. Present data suggest that terbinafine may be a useful alternative for chronic forms. Methods: A ran...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Edizioni FS
2016-03-01
|
| Series: | Journal of Health and Social Sciences |
| Subjects: | |
| Online Access: | http://journalhss.com/wp-content/uploads/JHHS1147-56.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595578019643392 |
|---|---|
| author | Gianfranco Schiraldi Salvatore Lo Cicero Claudio Rossetti Delia Colombo Michele Chiericozzi Elvana Kola Luigi Allegra |
| author_facet | Gianfranco Schiraldi Salvatore Lo Cicero Claudio Rossetti Delia Colombo Michele Chiericozzi Elvana Kola Luigi Allegra |
| author_sort | Gianfranco Schiraldi |
| collection | DOAJ |
| description | Background: The frequency of pulmonary aspergillosis has been increasing for decades. Standard oral treatment is associated with tolerability problems and interactions with commonly used medications. Present data suggest that terbinafine may be a useful alternative for chronic forms.
Methods: A randomised, double-blind, multicentre trial compared terbinafine (500 mg b.i.d) with itraconazole (200 mg b.i.d.) with respect to successful outcomes for up to 6 months in 24 patients
with chronic pulmonary aspergillosis. The primary end-point was a global clinical assessment using a 4-point rating scale, including (thorax) X-ray or Tc features. Secondary end-points were mycological response, duration of treatment and tolerability based on adverse events, haematology, biochemistry and urinalyses.
Results: The patients were randomly allocated to terbinafine or itraconazole. No patients discontinued terbinafine, while 2 of 12 patients discontinued itraconazole because of protocol violation
(n=1) or withdrawal of consent (n=1). The mean ± SD duration of the treatment was longer in the terbinafine group (139.8 ± 43.6 days vs 120.5 ± 41.8 days). The clinical success rate was also higher with terbinafine (91.7% vs 70.0%), as was the eradication rate (100% vs 75%). The proportion of patients who reported adverse events was higher with itraconazole (7 of 12 vs 3 of 12).
Conclusions: Terbinafine (500 mg b.i.d. for up to 6 months) is an effective, well-tolerated antifungal agent for the treatment of chronic infectious forms of pulmonary aspergillosis, representing a
valid alternative to treatment with itraconazole in these clinical forms, due to better clinical efficacy and safety and lower costs vs new azoles. |
| format | Article |
| id | doaj-art-ddda66264da54853ad0fa76d0e6029db |
| institution | Kabale University |
| issn | 2499-2240 2499-5886 |
| language | English |
| publishDate | 2016-03-01 |
| publisher | Edizioni FS |
| record_format | Article |
| series | Journal of Health and Social Sciences |
| spelling | doaj-art-ddda66264da54853ad0fa76d0e6029db2025-01-18T18:20:29ZengEdizioni FSJournal of Health and Social Sciences2499-22402499-58862016-03-0111475610.19204/2016/trbn7Terbinafine versus itraconazole: a long-term, randomized, double-blind, clinical trial in chronic pulmonary aspergillosis. A pilote studyGianfranco Schiraldi0Salvatore Lo Cicero1Claudio Rossetti2Delia Colombo3Michele Chiericozzi4Elvana Kola5Luigi Allegra6Pneumology Unit, IRCCS Auxologico, Milan, ItalyPneumology Department, Niguarda Hospital, Milan, ItalyNuclear Medicine Department, Niguarda Hospital, Milan, ItalyNovartis Pharma, ItalyVilla Marelli Institute, Niguarda Hospital, Milan, ItalyTB Department, Villa Marelli Institute, Niguarda Hospital, Milan, ItalyRespiratory Diseases; Milan University, ItalyBackground: The frequency of pulmonary aspergillosis has been increasing for decades. Standard oral treatment is associated with tolerability problems and interactions with commonly used medications. Present data suggest that terbinafine may be a useful alternative for chronic forms. Methods: A randomised, double-blind, multicentre trial compared terbinafine (500 mg b.i.d) with itraconazole (200 mg b.i.d.) with respect to successful outcomes for up to 6 months in 24 patients with chronic pulmonary aspergillosis. The primary end-point was a global clinical assessment using a 4-point rating scale, including (thorax) X-ray or Tc features. Secondary end-points were mycological response, duration of treatment and tolerability based on adverse events, haematology, biochemistry and urinalyses. Results: The patients were randomly allocated to terbinafine or itraconazole. No patients discontinued terbinafine, while 2 of 12 patients discontinued itraconazole because of protocol violation (n=1) or withdrawal of consent (n=1). The mean ± SD duration of the treatment was longer in the terbinafine group (139.8 ± 43.6 days vs 120.5 ± 41.8 days). The clinical success rate was also higher with terbinafine (91.7% vs 70.0%), as was the eradication rate (100% vs 75%). The proportion of patients who reported adverse events was higher with itraconazole (7 of 12 vs 3 of 12). Conclusions: Terbinafine (500 mg b.i.d. for up to 6 months) is an effective, well-tolerated antifungal agent for the treatment of chronic infectious forms of pulmonary aspergillosis, representing a valid alternative to treatment with itraconazole in these clinical forms, due to better clinical efficacy and safety and lower costs vs new azoles.http://journalhss.com/wp-content/uploads/JHHS1147-56.pdfterbinafine; itraconazole; treatment; pulmonary aspergillosis; positron emission tomography. |
| spellingShingle | Gianfranco Schiraldi Salvatore Lo Cicero Claudio Rossetti Delia Colombo Michele Chiericozzi Elvana Kola Luigi Allegra Terbinafine versus itraconazole: a long-term, randomized, double-blind, clinical trial in chronic pulmonary aspergillosis. A pilote study Journal of Health and Social Sciences terbinafine; itraconazole; treatment; pulmonary aspergillosis; positron emission tomography. |
| title | Terbinafine versus itraconazole: a long-term, randomized, double-blind, clinical trial in chronic pulmonary aspergillosis. A pilote study |
| title_full | Terbinafine versus itraconazole: a long-term, randomized, double-blind, clinical trial in chronic pulmonary aspergillosis. A pilote study |
| title_fullStr | Terbinafine versus itraconazole: a long-term, randomized, double-blind, clinical trial in chronic pulmonary aspergillosis. A pilote study |
| title_full_unstemmed | Terbinafine versus itraconazole: a long-term, randomized, double-blind, clinical trial in chronic pulmonary aspergillosis. A pilote study |
| title_short | Terbinafine versus itraconazole: a long-term, randomized, double-blind, clinical trial in chronic pulmonary aspergillosis. A pilote study |
| title_sort | terbinafine versus itraconazole a long term randomized double blind clinical trial in chronic pulmonary aspergillosis a pilote study |
| topic | terbinafine; itraconazole; treatment; pulmonary aspergillosis; positron emission tomography. |
| url | http://journalhss.com/wp-content/uploads/JHHS1147-56.pdf |
| work_keys_str_mv | AT gianfrancoschiraldi terbinafineversusitraconazolealongtermrandomizeddoubleblindclinicaltrialinchronicpulmonaryaspergillosisapilotestudy AT salvatorelocicero terbinafineversusitraconazolealongtermrandomizeddoubleblindclinicaltrialinchronicpulmonaryaspergillosisapilotestudy AT claudiorossetti terbinafineversusitraconazolealongtermrandomizeddoubleblindclinicaltrialinchronicpulmonaryaspergillosisapilotestudy AT deliacolombo terbinafineversusitraconazolealongtermrandomizeddoubleblindclinicaltrialinchronicpulmonaryaspergillosisapilotestudy AT michelechiericozzi terbinafineversusitraconazolealongtermrandomizeddoubleblindclinicaltrialinchronicpulmonaryaspergillosisapilotestudy AT elvanakola terbinafineversusitraconazolealongtermrandomizeddoubleblindclinicaltrialinchronicpulmonaryaspergillosisapilotestudy AT luigiallegra terbinafineversusitraconazolealongtermrandomizeddoubleblindclinicaltrialinchronicpulmonaryaspergillosisapilotestudy |